User profiles for "author:K de Vlam"

Kurt de Vlam

university hospitals leuven
Verified email at uzleuven.be
Cited by 18495

EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 …

…, TR Pedersen, L Jacobsson, K De Vlam… - Annals of the …, 2017 - ard.bmj.com
Patients with rheumatoid arthritis (RA) and other inflammatory joint disorders (IJD) have
increased cardiovascular disease (CVD) risk compared with the general population. In …

[HTML][HTML] European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies

…, M De Wit, H Dagfinrud, K De Vlam… - Annals of the …, 2012 - ard.bmj.com
Background Psoriatic arthritis (PsA) is a clinically heterogeneous disease. Clear consensual
treatment guidance focused on the musculoskeletal manifestations of PsA would be …

Treatment recommendations for psoriatic arthritis

…, P Helliwell, WH Boehncke, K De Vlam… - Annals of the …, 2009 - ard.bmj.com
Objective: To develop comprehensive recommendations for the treatment of the various
clinical manifestations of psoriatic arthritis (PsA) based on evidence obtained from a …

Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force

…, A Tanew, B Thio, D Veale, K De Vlam… - Annals of the …, 2018 - ard.bmj.com
Therapeutic targets have been defined for axial and peripheral spondyloarthritis (SpA) in
2012, but the evidence for these recommendations was only of indirect nature. These …

Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial

C Antoni, GG Krueger, K de Vlam, C Birbara… - Annals of the …, 2005 - ard.bmj.com
Objectives: To evaluate further in a phase III, double blind trial the efficacy of infliximab in
patients with active psoriatic arthritis (PsA), as observed in the smaller IMPACT trial …

A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of …

…, A Balanescu, A Dinte, K de Vlam… - Annals of the …, 2014 - ard.bmj.com
Introduction The objective was to develop a questionnaire that can be used to calculate a
score reflecting the impact of psoriatic arthritis (PsA) from the patients' perspective: the PsA …

[PDF][PDF] Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis.

…, E de Klerk, M Dougados, K De Vlam… - Outcome and disease …, 2003 - core.ac.uk
Objective: Our aim was to determine whether C-reactive protein (CRP) or erythrocyte
sedimentation rate (ESR) is more appropriate in measuring disease activity in ankylosing …

Three multicenter, randomized, double‐blind, placebo‐controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis

…, M Rischmueller, J Zochling, K De Vlam… - Arthritis & …, 2019 - Wiley Online Library
Objective To evaluate the efficacy and safety of ustekinumab in 3 randomized, placebo‐
controlled studies in patients with axial spondyloarthritis (SpA). Studies 1 and 2 included …

The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project)

…, ER Soriano, PP Tak, I Ujfalussy, K De Vlam… - Annals of the …, 2013 - ard.bmj.com
Objective To develop new composite disease activity indices for psoriatic arthritis (PsA).
Methods Data from routine clinic visits at multiple centres were collected in a systematic …

Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association.

K De Vlam, H Mielants, C Cuvelier… - The Journal of …, 2000 - europepmc.org
Objective To determine the overall prevalence of spondyloarthropathy (SpA) among patients
with inflammatory bowel disease (IBD)[Crohn's disease (CD) and ulcerative colitis (UC)] …